ArticleCell reports methods2021
An intravitreal implant injection method for sustained drug delivery into mouse eyes.
Article in Cell reports methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Direction-selective laterodorsal thalamic nucleus encodes optic flow and turning in spatial navigation.Neuron · 2025Article
- Inhibiting acute, axonal DLK palmitoylation is neuroprotective and avoids deleterious effects of cell-wide DLK inhibition.Nature communications · 2025Article
- Subretinal delivery of AAV5-mediated humanMolecular vision · 2025Article
- An improved method of transducing retinal ganglion cells using AAV via transpupillary injection in adult mouse eyes.Molecular vision · 2025Article
- A metabotropic glutamate receptor agonist enhances visual signal fidelity in a mouse model of retinitis pigmentosa.bioRxiv : the preprint server for biology · 2024Article
- An Autotaxin-Induced Ocular Hypertension Mouse Model Reflecting Physiological Aqueous Biomarker.Investigative ophthalmology & visual science · 2024Article
- Overview of processed excipients in ocular drug delivery: Opportunities so far and bottlenecks.Heliyon · 2024Review
- Development of an immunodiagnostic assay for the detection ofTurkish journal of biology = Turk biyoloji dergisi · 2024Article
- Biodegradable Long-Acting Injectables: Platform Technology and Industrial Challenges.Handbook of experimental pharmacology · 2024Article
- Multimodal photoacoustic microscopy, optical coherence tomography, and fluorescence imaging of USH2A knockout rabbits.Scientific reports · 2023Article
- Recombinant protein delivery enables modulation of the phototransduction cascade in mouse retina.Cellular and molecular life sciences : CMLS · 2023Article
- Review
- Development of a new surgical technique to infuse kynurenic acid to optic nerves in chickens for studying loss of myelination.Heliyon · 2023Article
- Therapeutic effect of ultra-long-lasting human C-peptide delivery against hyperglycemia-induced neovascularization in diabetic retinopathy.Theranostics · 2023Article
- Anesthesia and analgesia for common research models of adult mice.Laboratory animal research · 2022Review
- A protocol to inject ocular drug implants into mouse eyes.STAR protocols · 2022Article
- Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System.Gels (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Using small molecule drugs to treat eye diseases carries benefits of specificity, scalability, and transportability, but their efficacy is significantly limited by a fast intraocular clearance rate. Ocular drug implants (ODIs) present a compelling means for the slow and sustained release of small molecule drugs inside the eye. However, methods are needed to inject small molecule ODIs into animals with small eyes, such as mice, which are the primary genetic models for most human ocular diseases. Consequently, it has not been possible to fully investigate efficacy and ocular pharmacokinetics of ODIs. Here, we present a robust, cost-effective, and minimally invasive method called "mouse implant intravitreal injection" (MI3) to deliver ODIs into mouse eyes. This method will expand ODI research to cover the breadth of human eye diseases modeled in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.